» Articles » PMID: 39240400

Effective Use of Zoledronic Acid for Refractory Hypercalcemia in Neonatal Subcutaneous Fat Necrosis

Overview
Specialty Pediatrics
Date 2024 Sep 6
PMID 39240400
Authors
Affiliations
Soon will be listed here.
References
1.
Stefanko N, Drolet B . Subcutaneous fat necrosis of the newborn and associated hypercalcemia: A systematic review of the literature. Pediatr Dermatol. 2018; 36(1):24-30. DOI: 10.1111/pde.13640. View

2.
Chesover A, Harrington J, Mahmud F . Pamidronate as first-line treatment of hypercalcemia in neonatal subcutaneous fat necrosis: A case series. Paediatr Child Health. 2021; 26(1):e52-e56. PMC: 7850270. DOI: 10.1093/pch/pxz141. View

3.
Militello M, Re M, Vitaliti G, Finazzo F, Manzoni P, Vitaliti S . Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia. Am J Perinatol. 2019; 36(S 02):S134-S138. DOI: 10.1055/s-0039-1691777. View

4.
Bowden S, Mahan J . Zoledronic acid in pediatric metabolic bone disorders. Transl Pediatr. 2017; 6(4):256-268. PMC: 5682380. DOI: 10.21037/tp.2017.09.10. View